# Signals Article on Putative Target Q01196 for Acute Lymphoblastic Leukemia
Background
The putative target Q01196, associated with acute lymphoblastic leukemia (ALL), emerges as a candidate of interest for further exploration in therapeutic contexts. Preliminary findings suggest that Q01196 may be implicated in the biology of ALL, making it a potential target for precision medicine strategies. Given the urgent need for novel treatment options in ALL, this candidate warrants further validation to assess its therapeutic potential.Data-mining rationale
The exploration of Q01196 is grounded in a systematic data-mining approach that cross-referenced reviewed human entries from UniProt, specifically targeting acute lymphoblastic leukemia. This analysis encompassed 478 microarray datasets available in the NCBI Gene Expression Omnibus (GEO), including GDS:200322536, GDS:200254001, GDS:200253999, GDS:200253998, and GDS:200253996. Notably, while Q01196 has been identified in expression-profiling studies, it currently lacks any registered Phase 1 or higher clinical programs, highlighting a significant gap in its exploration as a therapeutic target.Why prior analyses may have missed this
Many of the GEO datasets utilized in this analysis were generated prior to the implementation of modern empirical-Bayes statistical methods, such as limma, which are essential for accurate differential expression analysis. The absence of appropriate multiple-testing corrections in earlier studies may have contributed to the underrecognition of Q01196's relevance in ALL. By re-analyzing these datasets with contemporary statistical techniques, we may uncover critical insights into the role of Q01196 in the pathogenesis of ALL.Reasoning for further validation
To establish the potential of Q01196 as a therapeutic target in ALL, the following experimental approaches are recommended: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to accurately identify differentially expressed genes. 2. Validate the top differentially expressed genes associated with Q01196 through quantitative PCR (qPCR) in an independent cohort of ALL patients to confirm expression patterns. 3. Investigate the tissue specificity of Q01196 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its relevance in ALL compared to other tissues. 4. Utilize pathway analysis tools such as STRING and OmniPath to explore the biological pathways associated with Q01196, providing context for its role in ALL. 5. If validation is achieved, assess the druggability of Q01196 through databases such as DGIdb and ChEMBL to evaluate its potential as a target for therapeutic intervention.References
- UniProt. Q01196. [UniProt](https://www.uniprot.org/uniprot/Q01196).
- NCBI GEO. GDS:200322536. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200322536).
- NCBI GEO. GDS:200254001. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200254001).
- NCBI GEO. GDS:200253999. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200253999).
- NCBI GEO. GDS:200253998. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200253998).
- NCBI GEO. GDS:200253996. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200253996).